Invivogen: Ruxolitinib

Ruxolitinib

20-abx076799
  • Ask for price
  • Ask for price
  • 25 mg
  • 5 mg

Human IgG antibody Laboratories manufactures the invivogen: ruxolitinib reagents distributed by Genprice. The Invivogen: Ruxolitinib reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact InVivoGen. Other Invivogen: products are available in stock. Specificity: Invivogen: Category: Ruxolitinib

Ruxolitinib phosphate

10.0mg
EUR 90

Ruxolitinib, Phosphate

25 mg
EUR 245
Description: Ruxolitinib, also known as INCB18424, is a potent and selective Janus kinase JAK1 and JAK2 inhibitor, with IC50s of 5.9 nM and 5.7 nM, respectively. It inhibited IL-6 and IL-23 effects at concentrations less than 50 nM. Ruxolitinib was effective in the rat adjuvant arthritis model and multiple murine models of arthritis.

Ruxolitinib, Phosphate

100 mg
EUR 385
Description: Ruxolitinib, also known as INCB18424, is a potent and selective Janus kinase JAK1 and JAK2 inhibitor, with IC50s of 5.9 nM and 5.7 nM, respectively. It inhibited IL-6 and IL-23 effects at concentrations less than 50 nM. Ruxolitinib was effective in the rat adjuvant arthritis model and multiple murine models of arthritis.

INCB018424 (Ruxolitinib)

5mg
EUR 362.4

Ruxolitinib phosphate

100 mg
EUR 224
Description: JAK1/JAK2 inhibitor

Ruxolitinib phosphate

25 mg
EUR 120
Description: JAK1/JAK2 inhibitor

Ruxolitinib phosphate

5 mg
EUR 40
Description: JAK1/JAK2 inhibitor

Chemicals information

Ruxolitinib, Phosphate

27059-1 25 mg
EUR 245
Description: Ruxolitinib, also known as INCB18424, is a potent and selective Janus kinase JAK1 and JAK2 inhibitor, with IC50s of 5.9 nM and 5.7 nM, respectively. It inhibited IL-6 and IL-23 effects at concentrations less than 50 nM. Ruxolitinib was effective in the rat adjuvant arthritis model and multiple murine models of arthritis.

Ruxolitinib, Phosphate

27059-2 100 mg
EUR 385
Description: Ruxolitinib, also known as INCB18424, is a potent and selective Janus kinase JAK1 and JAK2 inhibitor, with IC50s of 5.9 nM and 5.7 nM, respectively. It inhibited IL-6 and IL-23 effects at concentrations less than 50 nM. Ruxolitinib was effective in the rat adjuvant arthritis model and multiple murine models of arthritis.

Ruxolitinib phosphate

A3781-100 100 mg
EUR 224
Description: JAK1/JAK2 inhibitor

Ruxolitinib phosphate

A3781-25 25 mg
EUR 120
Description: JAK1/JAK2 inhibitor

Ruxolitinib phosphate

A3781-5 5 mg
EUR 40
Description: JAK1/JAK2 inhibitor

Ruxolitinib phosphate

A3781-5.1 10 mM (in 1mL DMSO)
EUR 44
Description: JAK1/JAK2 inhibitor

Ruxolitinib phosphate

T3043-10mg 10mg Ask for price
Description: Ruxolitinib phosphate

Ruxolitinib phosphate

T3043-1g 1g Ask for price
Description: Ruxolitinib phosphate

Ruxolitinib phosphate

T3043-1mg 1mg Ask for price
Description: Ruxolitinib phosphate

Ruxolitinib phosphate

T3043-50mg 50mg Ask for price
Description: Ruxolitinib phosphate

Ruxolitinib phosphate

T3043-5mg 5mg Ask for price
Description: Ruxolitinib phosphate

Ruxolitinib (phosphate)

HY-50858 5mg
EUR 142.8

Ruxolitinib Phosphate

R702005 100mg
EUR 1269
Description: 1092939-17-7

INCB018424 (Ruxolitinib)

E1KS1378 5mg
EUR 362.4

Ruxolitinib (INCB018424)

A3012-100 100 mg
EUR 224
Description: JAK inhibitor

Ruxolitinib (INCB018424)

A3012-25 25 mg
EUR 120
Description: JAK inhibitor

Ruxolitinib (INCB018424)

A3012-5 5 mg
EUR 56
Description: JAK inhibitor